Education
About Us
Working with TipRanks
Follow Us
Cerus Corporation (CERS)
:CERS
CERS Stock Chart & Stats
$1.63
-$0.02(-1.22%)
At close: 4:00 PM EST
$1.63
-$0.02(-1.22%)
Day’s Range― - ―
52-Week Range$1.12 - $2.24
Previous CloseN/A
Volume302.69K
Average Volume (3M)1.24M
Market Cap
$277.96M
Enterprise Value$291.35M
Total Cash (Recent Filing)$78.03M
Total Debt (Recent Filing)$98.90M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Feb 19, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding191,698,790
10 Day Avg. Volume1,096,198
30 Day Avg. Volume1,240,691
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue1.51
Enterprise Value/Gross Profit2.70
Enterprise Value/Ebitda-33.78
Forecast
1Y Price Target
$4.50Price Target Upside176.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Growth OpportunitiesCERS's valuation fails to reflect its growth opportunities, including a multilayered growth path supported by an expanding product portfolio and entry into new geographic territories.
Guidance And ForecastGuidance for the full year was raised, reflecting strength in the ongoing rollout of the novel IFC offering, and management is confident about meeting demand for IFC in the back half of the year.
Product PerformanceCERS reported results well ahead of expectations, with product revenue beating estimates, driven by strong performances in North America and EMEA regions.
Bears Say
Cerus News
CERS FAQ
What was Cerus Corporation’s price range in the past 12 months?
Cerus Corporation lowest stock price was $1.12 and its highest was $2.23 in the past 12 months.
What is Cerus Corporation’s market cap?
Cerus Corporation’s market cap is $277.96M.
When is Cerus Corporation’s upcoming earnings report date?
Cerus Corporation’s upcoming earnings report date is Feb 19, 2026 which is in 104 days.
How were Cerus Corporation’s earnings last quarter?
Cerus Corporation released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.028 by $0.028.
Is Cerus Corporation overvalued?
According to Wall Street analysts Cerus Corporation’s price is currently Undervalued.
Does Cerus Corporation pay dividends?
Cerus Corporation does not currently pay dividends.
What is Cerus Corporation’s EPS estimate?
Cerus Corporation’s EPS estimate is -0.01.
How many shares outstanding does Cerus Corporation have?
Cerus Corporation has 191,698,790 shares outstanding.
What happened to Cerus Corporation’s price movement after its last earnings report?
Cerus Corporation reported an EPS of $0 in its last earnings report, beating expectations of -$0.028. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cerus Corporation?
Currently, no hedge funds are holding shares in CERS
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (176.07% Upside)
$4.50 (176.07% Upside)
Hedge Fund Trend
Decreased
By 8.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $31.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.65%
12-Months-Change
Fundamentals
Return on Equity
-35.98%
Trailing 12-Months
Asset Growth
14.87%
Trailing 12-Months
Company Description
Cerus Corporation
Cerus Corporation (CERS) is a biomedical company focused on the development and commercialization of innovative technologies for blood safety. The company specializes in pathogen inactivation technologies designed to enhance the safety of blood transfusions and transplantation. Its core product is the INTERCEPT Blood System, which utilizes a proprietary technology to inactivate a broad range of pathogens in blood components, including platelets, plasma, and red blood cells. Cerus operates primarily in the healthcare sector, targeting hospitals, blood centers, and healthcare providers worldwide.
CERS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Cerus Corporation's earnings call for Q3 2025 highlighted significant revenue growth and positive financial performance, driven by strong demand for INTERCEPT products and successful international expansion efforts. However, the company faces challenges with gross margin pressures and regulatory delays in Europe. Despite these hurdles, the overall outlook remains optimistic with raised revenue guidance and continued focus on operational execution.View all CERS earnings summariesCERS Stock 12 Month Forecast
Average Price Target
$4.50
▲(176.07% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―
Ownership Overview
4.91% Insiders
14.83% Mutual Funds
0.84% Other Institutional Investors
59.95% Public Companies and
Individual Investors